ggt1 Antibody

What is GGT1 and why is it important in biomedical research?

GGT1 (Gamma-glutamyltranspeptidase 1) is a 569 amino acid ~65-70 kDa single pass, type II transmembrane glycoprotein also known as Leukotriene-C4 hydrolase, CD224, or Glutathione hydrolase 1. This protein forms an integral part of the cell antioxidant defense mechanism . GGT1 plays a crucial role in glutathione metabolism by transferring glutamyl moiety from glutathione to various amino acids and dipeptide acceptors, which maintains cellular redox balance and detoxifies harmful compounds . Its importance in research stems from its altered expression in various disease states, particularly liver diseases and certain cancers. Mutations in the GGT1 gene can lead to Glutathionuria (GLUTH), a condition also known as Gamma-glutamyltranspeptidase deficiency .

What types of GGT1 antibodies are available for research applications?

GGT1 antibodies are available in multiple formats to accommodate various experimental needs:

• Monoclonal antibodies: Such as clone 1F9, which is a mouse anti-human GGT1 IgG2a isotype antibody .

• Polyclonal antibodies: Including rabbit polyclonal antibodies that can detect GGT1 protein in both human and mouse samples .

• Various conjugated forms: GGT1 antibodies can be obtained in non-conjugated form or with various conjugates including:

  • Agarose

  • Horseradish peroxidase (HRP)

  • Phycoerythrin (PE)

  • Fluorescein isothiocyanate (FITC)

  • Multiple Alexa Fluor® options

The choice between monoclonal and polyclonal antibodies depends on the specific research requirements, with monoclonals offering higher specificity for particular epitopes and polyclonals providing broader epitope recognition.

What are the main applications of GGT1 antibodies in laboratory techniques?

GGT1 antibodies have demonstrated utility across multiple laboratory techniques:

For example, in Western blot applications, GGT1 antibody (GTX101198) has been used at a 1:1000 dilution to detect GGT1 protein in various whole cell lysates, including Neuro2A, GL261, NIH-3T3, and Raw264.7 cell lines .

How do I optimize GGT1 antibody performance for immunohistochemistry?

Optimizing GGT1 antibody performance for immunohistochemistry requires careful consideration of several parameters:

Sample preparation:

• For paraffin-embedded tissues, appropriate antigen retrieval methods are essential. Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is commonly employed.

• For the GGT129 antibody (used for GGT1), dilution at 1:500 (approximately 1:6700 relative to starting serum concentration) has been reported to be effective .

Detection protocol:

• A protocol using affinity-purified GGT5-Ab797 diluted 1:100 and incubated on tissue for 32 minutes at 37°C has been documented.

• Visualization can be achieved with DAB Detection Systems including H₂O₂ pretreatment and HRP-labeled secondary antibodies.

• Counterstaining with hematoxylin helps provide cellular context .

Controls:

• Include negative controls by processing tissue sections without the primary antibody.

• Normal human kidney and adrenal gland tissues have been used as positive controls for GGT1 immunolabeling .

Expected results:

• In human kidney, GGT1 is expressed exclusively in proximal tubules, localizing to the apical surface of epithelial cells.

• In human liver, GGT1 shows a pattern distinct from GGT5, which is important to consider when interpreting results .

What are the key differences between GGT1 and GGT5 antibodies in tissue expression patterns?

Understanding the distinct tissue expression patterns of GGT1 and GGT5 is crucial for proper experimental design and interpretation:

Kidney expression patterns:

• GGT1: Expressed exclusively in proximal tubules, localizing to the apical surface of epithelial cells.

• GGT5: Strongly expressed in interstitial cells between renal tubules .

Liver expression patterns:

• GGT1: Expression pattern differs from that of GGT5.

• GGT5: Strongly expressed by Kupffer cells (tissue-fixed macrophages) and weakly expressed in hepatocytes .

Functional differences:

• While GGT5 converts leukotriene C4 to leukotriene D4, it does not act on the synthetic substrates typically used in GGT assays.

• This functional difference highlights GGT1's specific role and the importance of using the correct antibody for each target .

Researchers should carefully select the appropriate antibody based on the target of interest and validate specificity in their experimental system, particularly when studying tissues where both proteins are expressed.

How can I analyze glycosylation patterns on GGT1 using antibody-based approaches?

The analysis of GGT1 glycosylation patterns is particularly relevant as they are tissue-specific and can change in disease states such as tumors. The antibody-lectin sandwich array (ALSA) platform offers a microanalytical approach for characterizing the N-glycan content of GGT1 in complex biological samples .

ALSA methodology for GGT1 glycan analysis:

• Immobilization: GGT1 antibody is chemically modified and printed on the platform to prevent interactions with lectin probes or secondary antibodies.

• Capture: The immobilized antibody captures GGT1 from detergent-extracted membrane proteins.

• Lectin probing: Different lectins are used to detect specific glycan structures on the captured GGT1.

• Detection and analysis: The lectin binding patterns reveal differences in glycan content .

Lectins used for GGT1 glycan characterization include:

• MVN (Microvirin): Specifically recognizes high-mannose-type N-glycans, which are distinctive of GGT1 expressed by many tumors.

• Pha-E (Phaseolus vulgaris Erythroagglutinin): Shows strong binding to kidney GGT1 but not to liver-derived or Pichia pastoris-expressed GGT1.

• DSL (Datura stramonium Lectin): Exhibits strong binding preference for kidney GGT1 and modest interaction with liver GGT1 .

This approach allows characterization of GGT1 glycosylation using sub-microgram quantities of total protein within complex tissue samples, making it valuable for biomarker development and disease monitoring .

What controls should I include when using GGT1 antibodies in my experiments?

Proper controls are essential for ensuring the validity and reproducibility of experiments using GGT1 antibodies:

Positive controls:

• Tissue controls: Normal human kidney tissue is an excellent positive control for GGT1 detection, as it shows strong and specific expression in proximal tubules .

• Cell line controls: Cell lines known to express GGT1, such as Neuro2A, GL261, NIH-3T3, Raw264.7, and C2C12, can serve as positive controls for Western blot applications .

Negative controls:

• Antibody omission: Process samples without the primary antibody to assess background staining.

• Isotype controls: Use an irrelevant antibody of the same isotype (e.g., mouse IgG2a for the 1F9 clone) to identify non-specific binding .

• Known negative tissues/cells: Include samples that do not express GGT1 based on previous literature.

Specificity controls:

• Blocking peptides: Pre-incubation of the antibody with the immunizing peptide (when available) should abolish specific staining.

• siRNA knockdown: For cell culture work, siRNA knockdown of GGT1 should reduce antibody signal proportionately.

The implementation of these controls will help validate antibody specificity and ensure the reliability of experimental findings.

How can I distinguish between different GGT isoforms in my experiments?

Distinguishing between different GGT isoforms, particularly GGT1 and GGT5, requires careful experimental design:

Antibody selection:

• Use highly specific antibodies validated for the particular isoform. For example, the clone 1F9 for GGT1 or GGT5-Ab797 for GGT5 .

Expression pattern analysis:

• Take advantage of the known differential tissue expression patterns. For instance, in the kidney, GGT1 is expressed in proximal tubules while GGT5 is expressed in interstitial cells .

Molecular weight considerations:

• GGT1 is a ~65-70 kDa protein , whereas other isoforms may have different molecular weights. Use this information when interpreting Western blot results.

Functional assays:

• GGT1 and GGT5 have different substrate specificities. GGT5 converts leukotriene C4 to leukotriene D4 but does not act on synthetic substrates used in standard GGT assays .

Glycosylation pattern analysis:

• Different GGT isoforms exhibit distinct glycosylation patterns that can be characterized using lectins such as MVN, Pha-E, and DSL .

By employing a combination of these approaches, researchers can more confidently distinguish between different GGT isoforms in their experimental systems.

What are the common issues in GGT1 antibody applications and how can they be resolved?

Researchers frequently encounter challenges when working with GGT1 antibodies. Here are common issues and their potential solutions:

Non-specific binding in Western blots:

• Problem: Multiple bands observed beyond the expected ~65-70 kDa size.

• Solution: Optimize blocking conditions (try different blocking agents such as BSA or milk), increase antibody dilution, reduce incubation time, or include additional washing steps. Note that apparent non-specific bands may sometimes represent the dissociated heavy chain of the rabbit IgG used in immunoprecipitation experiments .

Weak or absent signal in immunohistochemistry:

• Problem: Poor or no staining despite known expression of GGT1 in the target tissue.

• Solution: Optimize antigen retrieval methods, adjust antibody concentration, extend incubation time, or try a more sensitive detection system. For GGT1, a protocol using incubation at 37°C for 32 minutes has been reported to be effective .

Cross-reactivity with other GGT isoforms:

• Problem: Difficulty distinguishing between GGT1 and other isoforms such as GGT5.

• Solution: Select antibodies raised against unique epitopes of GGT1. The monoclonal antibody clone 1F9 is specific for human GGT1 . Validate specificity using tissues with known differential expression patterns, such as kidney proximal tubules for GGT1 and interstitial cells for GGT5 .

Variable glycosylation affecting detection:

• Problem: Inconsistent detection due to tissue-specific or disease-related glycosylation differences.

• Solution: Be aware that GGT1 exhibits significant heterogeneity due to different glycosylation patterns rather than gene product variations . Consider using antibodies that recognize protein epitopes not affected by glycosylation or employ the ALSA platform to characterize glycosylation patterns .

How can GGT1 antibodies be used in biomarker research for cancer detection?

GGT1 antibodies offer significant potential for cancer biomarker research due to several key factors:

GGT1 is shed from the cell surface in various disease states, including tumor formation, and can be detected in serum . The N-glycans on human GGT1 (hGGT1) have been shown to be tissue-specific, with tumor-specific changes also observed . This makes GGT1 glycosylation patterns a promising biomarker for detecting tumors and monitoring their progression during treatment.

Methodological approaches for cancer biomarker research:

• Antibody-lectin sandwich array (ALSA):

  • This microanalytical technique allows characterization of N-glycan content of hGGT1 in complex biological samples using sub-microgram quantities of protein.

  • The platform can reveal distinctions in glycan content on hGGT1 from different sources, which correlates with known, quantifiable differences in glycan content identified by mass spectrometry .

• Microvirin (MVN) lectin application:

  • MVN specifically recognizes high-mannose-type N-glycans, which are distinctive of hGGT1 expressed by many tumors.

  • This lectin can be incorporated into detection platforms to identify tumor-specific glycosylation patterns .

• Serum GGT1 monitoring:

  • Elevated GGT1 levels in serum serve as an early biomarker for hepatocellular carcinoma.

  • GGT1 antibodies can be used in ELISA or other immunoassay formats to quantify serum levels .

These approaches enable researchers to investigate GGT1 as a biomarker for early detection of cancer, stratification of patients, and monitoring treatment efficacy.

What advanced approaches can be used to study the structure-function relationship of GGT1 using antibodies?

Studying the structure-function relationship of GGT1 requires sophisticated experimental approaches in which antibodies play a central role:

Epitope mapping:

• Different antibodies recognizing distinct epitopes on GGT1 can be used to understand which regions of the protein are crucial for its function.

• For example, antibodies targeting the mouse anti Human GGT1 antibody (clone 1F9) that recognizes an epitope corresponding to amino acids 381-471 of human GGT1 can provide insights into this region's functional importance.

Functional inhibition studies:

• Antibodies that bind to specific domains of GGT1 can be tested for their ability to inhibit enzymatic activity.

• Comparing the inhibitory effects of antibodies targeting different epitopes helps identify functionally critical regions.

Conformational analysis:

• Conformation-specific antibodies can detect changes in GGT1 structure under different physiological or pathological conditions.

• This approach is particularly valuable for understanding how post-translational modifications like glycosylation affect protein conformation and function.

Protein-protein interaction studies:

• Antibodies can be used in co-immunoprecipitation experiments to identify GGT1 binding partners.

• This helps elucidate the protein's role in larger complexes and signaling pathways.

Post-translational modification analysis:

• The combination of GGT1 antibodies with glycan-specific lectins in platforms like ALSA provides insights into how glycosylation patterns influence protein function .

• This is especially relevant given that GGT1 shows significant heterogeneity due to different glycosylation patterns rather than gene product variations .

What are the latest methodologies for studying GGT1 in complex tissue microenvironments?

Recent advancements have enhanced our ability to study GGT1 in complex tissue contexts:

Antibody-lectin sandwich array (ALSA):

• This emerging platform allows characterization of GGT1 glycosylation patterns using minimal amounts of protein from complex biological samples.

• The technique has been validated for distinguishing GGT1 from normal human liver tissue, normal human kidney tissue, and recombinant GGT1 expressed in Pichia pastoris .

Multiplex immunofluorescence imaging:

• Combining GGT1 antibodies with markers for specific cell types allows for precise localization within heterogeneous tissues.

• This approach has revealed that in the liver, GGT1 expression patterns differ from GGT5, which is strongly expressed by Kupffer cells and weakly by hepatocytes .

Tissue-specific glycosylation analysis:

• Different lectins (MVN, Pha-E, DSL) exhibit distinctive binding preferences for GGT1 from different tissue sources.

• For example, Pha-E strongly binds to kidney GGT1 but not to liver-derived GGT1, while DSL shows strong binding preference for kidney GGT1 and modest interaction with liver GGT1 .

Single-cell analysis techniques:

• Integration of GGT1 antibodies with single-cell technologies allows for the analysis of GGT1 expression and modification at the individual cell level within complex tissues.

• This enables the identification of specific cell populations with altered GGT1 expression or glycosylation in disease states.

These methodologies provide researchers with powerful tools to investigate GGT1 biology in physiologically relevant contexts, facilitating a deeper understanding of its role in health and disease.

How might new antibody technologies advance GGT1 research in the coming years?

Emerging antibody technologies hold significant promise for advancing GGT1 research:

Nanobodies and single-domain antibodies:

• These smaller antibody fragments offer improved tissue penetration and may access epitopes unavailable to conventional antibodies.

• Their application could enhance in vivo imaging of GGT1 and provide new insights into its distribution and dynamics.

Antibody engineering for improved specificity:

• Engineered antibodies with enhanced specificity for GGT1 over other GGT family members will enable more precise studies of isoform-specific functions.

• This is particularly important given the distinct tissue expression patterns and functions of GGT1 and GGT5 .

Multiplexed antibody technologies:

• Advances in multiplexed imaging and detection will allow simultaneous visualization of GGT1 along with multiple other markers.

• This will facilitate comprehensive analysis of GGT1's role in complex cellular networks and signaling pathways.

Antibody-drug conjugates (ADCs):

• Leveraging GGT1's differential expression in certain cancers, ADCs targeting GGT1 could represent a novel therapeutic approach.

• Research using antibodies to map expression patterns will inform the development of such targeted therapies.

Integrated glycoproteomic approaches:

• Combining antibody-based isolation with advanced mass spectrometry techniques will enhance our understanding of GGT1 glycosylation in different physiological and pathological states.

• This integrated approach will build upon current work using the ALSA platform to characterize GGT1 glycosylation patterns .

What are the remaining challenges in standardizing GGT1 antibody-based assays for clinical applications?

Despite progress in GGT1 antibody technology, several challenges remain for clinical standardization:

Glycosylation heterogeneity:

• GGT1 shows significant heterogeneity due to different glycosylation patterns rather than gene product variations .

• This creates challenges for developing standardized assays, as the glycosylation profile can vary by tissue source and disease state.

• Solutions may involve targeting conserved protein epitopes or developing panels of glycan-specific detection methods.

Cross-reactivity concerns:

• Ensuring absolute specificity for GGT1 over other GGT family members remains challenging.

• Rigorous validation using tissues with known differential expression, such as kidney and liver samples , is essential for clinical applications.

Quantification standardization:

• Establishing universally accepted standards for GGT1 quantification across different sample types and assay platforms.

• This requires collaborative efforts to develop reference materials and calibrators that account for the protein's heterogeneity.

Pre-analytical variables:

• Standardizing sample collection, processing, and storage procedures to minimize variability in GGT1 detection.

• These factors can significantly impact antibody binding and assay performance, particularly for modified forms of GGT1.

Clinical validation:

• Correlating antibody-based GGT1 measurements with clinical outcomes to establish diagnostic, prognostic, or predictive value.

• This requires large-scale, well-designed clinical studies across diverse patient populations.

Addressing these challenges will be crucial for translating GGT1 antibody research into clinically useful applications, particularly in cancer detection and monitoring.